ArticleOncotarget2015
MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model.NPJ genomic medicine · 2024Article
- Aberrant stem cell and developmental programs in pediatric leukemia.Frontiers in cell and developmental biology · 2024Review
- MicroRNA profiling of paediatric AML withOncology reports · 2022Article
- Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation.South Asian journal of cancer · 2022Article
- Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.International journal of molecular sciences · 2022Review
- Identification of key miRNAs in prostate cancer progression based on miRNA-mRNA network construction.Computational and structural biotechnology journal · 2022Article
- MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.Clinical and translational medicine · 2021Article
- Article
- Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis.BioMed research international · 2020Article
- Phenotype-genotype network construction and characterization: a case study of cardiovascular diseases and associated non-coding RNAs.Database : the journal of biological databases and curation · 2020Article
- Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer.Clinical and translational medicine · 2019Article
- Exosomal MiRNAs in Pediatric Cancers.International journal of molecular sciences · 2019Review
- Tumor classification and biomarker discovery based on the 5'isomiR expression level.BMC cancer · 2019Article
- High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.Cancer cell international · 2019Article
- NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.BMC cancer · 2018Article
- MiRNA Dysregulation in Childhood Hematological Cancer.International journal of molecular sciences · 2018Review
- A novel scoring system for acute myeloid leukemia risk assessment based on the expression levels of six genes.International journal of molecular medicine · 2018Article
- Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.Journal of translational medicine · 2018Article
- Diagnostic and prognostic relevance of serum miR-195 in pediatric acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2018Article
- Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) in children is a complex and heterogeneous disease. The identification of reliable and stable molecular biomarkers for diagnosis, especially early diagnosis, remains a significant therapeutic challenge. Aberrant microRNA expression could be used for cancer diagnosis and treatment selection. Here, we describe a novel bioinformatics model for the prediction of microRNA biomarkers for the diagnosis of paediatric AML based on computational functional analysis of the microRNA regulatory network substructure. microRNA-196b, microRNA-155 and microRNA-25 were identified as putative diagnostic biomarkers for pediatric AML. Further systematic analysis confirmed the association of the predicted microRNAs with the leukemogenesis of AML. In vitro q-PCR experiments showed that microRNA-155 is significantly overexpressed in children with AML and microRNA-196b is significantly overexpressed in subgroups M4-M5 of the French-American-British classification system. These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4-M5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.